Ivermectin and Mebendazole for Stage 4 Cancer
See compelling evidence for the use of ivermectin and benzimidazoles (fenbendazole and mebendazole) in patients with stage 4 cancers.
Recent research (a compilation of 270 case reports) has sparked interest in the potential of two well-known medications, Ivermectin and Mebendazole, as adjunctive treatments for Stage 4 cancer patients. Traditionally used as antiparasitic agents, these drugs have shown promise in laboratory studies for their ability to inhibit cancer cell growth and enhance the effectiveness of existing therapies. Compelling evidence suggests that these medications may work synergistically with conventional cancer treatments, offering hope for improved patient outcomes.
While clinical applications are still in the early stages, the findings encourage patients and healthcare providers to explore these therapies further. This is an exciting time in oncology, as new avenues for treatment continue to emerge, providing hope for those facing advanced stages of cancer.
For a deeper dive into the studies and insights surrounding Ivermectin and Mebendazole, I encourage you to read more here or contact me to discuss whether Ivermectin and/or Mebendazole may be a good addition to your regimen.
Key Link Between Microclots and Immune Response in Long COVID
Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients.
For those struggling with Long COVID, the search for answers can be frustrating. New scientific research reveals the complex biological changes that may be driving the condition. A study in the Journal of Medical Virology identifies a critical connection between the persistent microclots found in Long COVID patients and a specific component of the body's immune response. The research confirms that patients with Long COVID have significantly higher amounts of tiny, anomalous blood clots (microclots) that are difficult for the body to break down.
There is a structural link between these microclots and Neutrophil Extracellular Traps (NETs). NETs are web-like structures released by immune cells to trap pathogens, but their overproduction can cause inflammation and thrombosis. Researchers found that in Long COVID patients, these NETs are physically bound to the microclots, acting as a scaffold that makes them more stable and resistant to being cleared from circulation. This combination of clotting and persistent immune activation could be a major factor contributing to widespread symptoms.
This research deepens our understanding of Long COVID's underlying causes and creates new diagnostic possibilities. Identifying and measuring both microclots and NETs markers could lead to more accurate tests for diagnosing and monitoring the condition. Understanding this thromboinflammatory process also offers new targets for treatments aimed at breaking down these persistent microclots and calming the dysregulated immune response.
Read the full Journal of Medical Virology article for a detailed look at the study's methods and findings. Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients